Li Ming-Xue, Chen Chun-Ling, Ling Chun-Sheng, Zhou Jing, Ji Bian-Sheng, Wu Yan-Juan, Niu Jing-Yang
Institute of Molecular and Crystal Engineering, Henan University, Kaifeng, PR China.
Bioorg Med Chem Lett. 2009 May 15;19(10):2704-6. doi: 10.1016/j.bmcl.2009.03.135. Epub 2009 Mar 29.
A series of thiosemicarbazone ligands, HL(1) (2-acetylpyrazine thiosemicarbazone), HL(2) (2-acetylpyrazine N(4)-methylthiosemicarbazone), HL(3) (2-benzoylpyridine thiosemicarbazone) and HL(4) (2-benzoylpyridine N(4)-methylthiosemicarbazone), have been synthesized. The crystal structure of HL(1) has been determined by single-crystal X-ray diffraction. Hydrogen bonds link the different components to stabilize the crystal structure. The antitumor activity of the four ligands were tested against K562 leucocythemia and BEL7402 liver cancer cell lines. All the thiosemicarbazones showed significant antitumor activity. Different substituents on the ligands show different levels of antitumor activity. By comparison with the other thiosemicarbazone species studied, HL(4) with substitution at N(4) position in thiosemicarbazone along with 2-benzoylpyridine is the most active thiosemicarbazone ligand with IC(50)=0.002microm in the K562 leucocythemia cell line and 0.138microm in the BEL7402 liver cancer cell line, respectively.
已合成了一系列硫代氨基脲配体,HL(1)(2-乙酰基吡嗪硫代氨基脲)、HL(2)(2-乙酰基吡嗪N(4)-甲基硫代氨基脲)、HL(3)(2-苯甲酰基吡啶硫代氨基脲)和HL(4)(2-苯甲酰基吡啶N(4)-甲基硫代氨基脲)。通过单晶X射线衍射测定了HL(1)的晶体结构。氢键连接不同组分以稳定晶体结构。测试了这四种配体对K562白血病细胞系和BEL7402肝癌细胞系的抗肿瘤活性。所有硫代氨基脲均显示出显著的抗肿瘤活性。配体上的不同取代基表现出不同程度的抗肿瘤活性。与所研究的其他硫代氨基脲种类相比,硫代氨基脲中N(4)位有取代且带有2-苯甲酰基吡啶的HL(4)是活性最高的硫代氨基脲配体,在K562白血病细胞系中的IC(50)分别为0.002微摩尔,在BEL7402肝癌细胞系中的IC(50)为0.138微摩尔。